Posted by Michael Wonder on 22 Jan 2019
Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the treatment of psoriatic arthritis in adult patients
21 January 2019 - Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis in adult patients.
Sandoz Canada aannounced today that Health Canada has approved Erelzi (etanercept), a biosimilar of Enbrel (etanercept), for the treatment of psoriatic arthritis in adult patients, making Erelzi the only etanercept biosimilar to have obtained approval for this indication in Canada.
More specifically, Sandoz Canada Inc. received a Notice of Compliance from Health Canada on 17 January 2019 for Erelzi to be used for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis. Erelzi can be used in combination with methotrexate in adult patients who do not respond adequately to methotrexate alone.
